ZA958800B - Methods of inhibiting physiological conditions associaed with an excess of neuropeptide y - Google Patents

Methods of inhibiting physiological conditions associaed with an excess of neuropeptide y

Info

Publication number
ZA958800B
ZA958800B ZA958800A ZA958800A ZA958800B ZA 958800 B ZA958800 B ZA 958800B ZA 958800 A ZA958800 A ZA 958800A ZA 958800 A ZA958800 A ZA 958800A ZA 958800 B ZA958800 B ZA 958800B
Authority
ZA
South Africa
Prior art keywords
associaed
neuropeptide
excess
methods
physiological conditions
Prior art date
Application number
ZA958800A
Other languages
English (en)
Inventor
Bruns Jeffry Howbert Jr
Donald Richard Gehlert
James Jeffry Howbert
William Henry Walker Lunn
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA958800B publication Critical patent/ZA958800B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA958800A 1994-10-20 1995-10-18 Methods of inhibiting physiological conditions associaed with an excess of neuropeptide y ZA958800B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/326,675 US6562862B1 (en) 1994-10-20 1994-10-20 Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y

Publications (1)

Publication Number Publication Date
ZA958800B true ZA958800B (en) 1997-04-18

Family

ID=23273204

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA958800A ZA958800B (en) 1994-10-20 1995-10-18 Methods of inhibiting physiological conditions associaed with an excess of neuropeptide y

Country Status (19)

Country Link
US (5) US6562862B1 (xx)
EP (1) EP0785785A4 (xx)
JP (1) JPH10507757A (xx)
KR (1) KR970706818A (xx)
CN (1) CN1091598C (xx)
AU (1) AU689664B2 (xx)
CA (1) CA2200990A1 (xx)
CZ (1) CZ287411B6 (xx)
FI (1) FI971635A (xx)
HU (1) HUT76852A (xx)
IL (1) IL115663A (xx)
MY (1) MY132056A (xx)
NO (1) NO971520D0 (xx)
NZ (1) NZ295575A (xx)
RU (1) RU2188015C2 (xx)
TW (1) TW410156B (xx)
UA (1) UA46744C2 (xx)
WO (1) WO1996012490A1 (xx)
ZA (1) ZA958800B (xx)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5494929A (en) * 1995-01-12 1996-02-27 Eli Lilly And Company Methods of inhibiting growth hormone effects
US5532254A (en) * 1995-06-07 1996-07-02 Eli Lilly And Company Modulation of calcium channels using benzothiophenes
US5840747A (en) * 1995-06-07 1998-11-24 Eli Lilly And Company Calcium channel antagonists
EP0759441A3 (en) * 1995-06-30 1999-06-30 Eli Lilly And Company Methods of treating neuropeptide Y-associated conditions
AU730137B2 (en) * 1996-01-24 2001-03-01 H. Lundbeck A/S DNA encoding galanin GALR2 receptors and uses thereof
US5972624A (en) * 1996-01-24 1999-10-26 Synaptic Pharmaceutical Corporation Method of identifying ligands which bind recombinant galanin receptor (GALR2)
US6113876A (en) * 1996-01-29 2000-09-05 Eli Lilly And Company Methods of increasing sphincter competence
AU732473B2 (en) * 1996-01-29 2001-04-26 Eli Lilly And Company Methods of increasing sphincter competence
JP2001502296A (ja) 1996-08-23 2001-02-20 アラネックス コーポレーション ニューロペプチド―ｙリガンド
US6329197B2 (en) 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
US5900418A (en) * 1997-02-10 1999-05-04 Synapse Pharmaceuticals International, Inc. Method for treatment of obesity
CA2251580A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amides as npy5 receptor antagonists
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
US6048900A (en) * 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
WO1998035957A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
US6258837B1 (en) * 1997-04-23 2001-07-10 Banyu Pharmaceutical Co., Ltd. Neuropeptide Y receptor antagonist
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
CA2293621C (en) 1997-08-05 2003-12-30 Robert Lee Dow 4-aminopyrrole(3,2-d) pyrimidines as neuropeptide y receptor antagonists
PT896822E (pt) * 1997-08-05 2003-07-31 Pfizer Prod Inc 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
US6008232A (en) * 1997-08-20 1999-12-28 Eli Lilly And Company Methods for preventing headaches
AU9106198A (en) * 1997-08-21 1999-03-08 Eli Lilly And Company Methods for inhibiting temporomandibular disorders
AU9105598A (en) * 1997-08-21 1999-03-08 Eli Lilly And Company Methods for inhibiting fibrous inflammatory disease and riedel's thyroiditis
US5990129A (en) * 1997-09-23 1999-11-23 Eli Lilly And Company Methods for regulating trkA expression
US20050107327A1 (en) * 1997-12-19 2005-05-19 Hormos Medical Corporation Method for reducing overproduction of neuropeptide Y in an individual
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
GB2344050A (en) * 1998-11-26 2000-05-31 Ferring Bv Agents useful in the treatment of reproductive disorders.
DE69922918T2 (de) 1999-01-27 2006-03-30 Pfizer Products Inc., Groton Neuropeptid Y Antagonisten
KR20010101931A (ko) 1999-02-03 2001-11-15 피터 지. 스트링거 α1-아드레날린성 수용체 길항제
DE19905961A1 (de) * 1999-02-12 2000-08-17 Stefan Neubauer Verwendung von Östrogenen zur Behandlung der Herzinsuffizienz
WO2000051623A2 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
WO2000066578A1 (en) 1999-04-30 2000-11-09 Pfizer Products Inc. Compounds for the treatment of obesity
ES2258476T3 (es) * 1999-09-30 2006-09-01 Neurogen Corporation Ciertos heterociclos sustituidos con alquilendiaminas.
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
WO2001053477A1 (en) * 2000-01-20 2001-07-26 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of neuropeptide y activity
JP2001261674A (ja) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
US6511984B2 (en) 2000-03-30 2003-01-28 Pfizer Inc. Neuropeptide Y antagonists
US6358991B2 (en) 2000-07-06 2002-03-19 American Home Products Corporation Methods of treating neuropeptide Y-related conditions
IL145876A0 (en) * 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
US20060165683A1 (en) 2001-12-05 2006-07-27 Gerard Karsenty Methods and compositions for control of bone formation via modulation of sympathetic tone
US6958347B2 (en) * 2002-12-18 2005-10-25 Pfizer Inc. Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
US6949564B2 (en) * 2002-12-18 2005-09-27 Pfizer Inc. NPY-5 antagonists
JP2004224756A (ja) * 2003-01-24 2004-08-12 Sumika Fine Chemicals Co Ltd ２，６−ジハロゲノ−８−置換−プリン化合物およびその製造方法
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
DE602004026289D1 (de) 2003-05-05 2010-05-12 Probiodrug Ag Glutaminylcyclase-hemmer
ES2228268B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
US20050137142A1 (en) 2003-11-03 2005-06-23 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
EP1713780B1 (en) 2004-02-05 2012-01-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
PT2275098E (pt) 2004-05-04 2012-08-29 Hormos Medical Ltd Novas formulações orais de ospemifeno
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
CA2588087A1 (en) * 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat
EP1877076A4 (en) * 2005-04-15 2012-02-01 Regenertech Pty Ltd USE OF NEUROPEPTIDES Y (NPY) AND AGONIST OF ANTAGONISTS THEREOF FOR REGENERATING TISSUES
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
EP2821385B1 (en) * 2007-02-14 2016-07-27 Hormos Medical Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
SI2225261T1 (sl) 2007-12-03 2016-07-29 Obe Therapy Biotechnology Boropeptidni inhibitorji enteropeptidaze in njihove uporabe pri zdravljenju debelosti, prekomerne teže in/ali bolezni, povezanih z nenormalno presnovo maščob
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN102791704B (zh) 2010-03-10 2015-11-25 前体生物药物股份公司 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
JP6174156B2 (ja) 2012-10-19 2017-08-02 フェルミオン オサケ ユキチュア オスペミフェンの製造方法
AU2014219283C1 (en) * 2013-02-19 2016-10-27 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4891357A (en) * 1985-02-11 1990-01-02 University Of Florida Methods and compositions for stimulation of appetite
US5075321A (en) 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
JP3157882B2 (ja) 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
AU672182B2 (en) 1991-11-27 1996-09-26 Novo Nordisk A/S Piperidine derivatives and their use in treating psychosis
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5482949A (en) 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
US5445941A (en) 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
ZA944377B (en) 1993-06-24 1995-12-20 Lilly Co Eli Hypoglycemic agents
TW303299B (xx) 1993-07-22 1997-04-21 Lilly Co Eli
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5457113A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
US5574047A (en) 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair
US5447941A (en) * 1993-12-21 1995-09-05 Eli Lilly And Company Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
US5441965A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5476862A (en) 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
NO944910L (no) 1993-12-21 1995-06-22 Lilly Co Eli Fremgangsmåte for å inhibere obsessive-kompulsive tilstander og spiseforstyrrelser
US5492927A (en) 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5439931A (en) 1993-12-21 1995-08-08 Eli Lilly And Company Method for increasing libido in post-menopausal women
US5578613A (en) 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US6417198B1 (en) * 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women

Also Published As

Publication number Publication date
FI971635A0 (fi) 1997-04-17
RU2188015C2 (ru) 2002-08-27
EP0785785A1 (en) 1997-07-30
AU689664B2 (en) 1998-04-02
MY132056A (en) 2007-09-28
HUT76852A (en) 1997-12-29
IL115663A0 (en) 1996-01-19
CZ287411B6 (en) 2000-11-15
NO971520L (no) 1997-04-03
WO1996012490A1 (en) 1996-05-02
KR970706818A (ko) 1997-12-01
US6562862B1 (en) 2003-05-13
FI971635A (fi) 1997-04-17
US5576337A (en) 1996-11-19
CZ115997A3 (en) 1997-10-15
IL115663A (en) 1999-08-17
UA46744C2 (uk) 2002-06-17
EP0785785A4 (en) 1998-11-11
US5567715A (en) 1996-10-22
CN1160998A (zh) 1997-10-01
CN1091598C (zh) 2002-10-02
US5567714A (en) 1996-10-22
JPH10507757A (ja) 1998-07-28
CA2200990A1 (en) 1996-05-02
TW410156B (en) 2000-11-01
US5504094A (en) 1996-04-02
AU3895595A (en) 1996-05-15
MX9702853A (es) 1997-07-31
NO971520D0 (no) 1997-04-03
NZ295575A (en) 2000-06-23

Similar Documents

Publication Publication Date Title
ZA958800B (en) Methods of inhibiting physiological conditions associaed with an excess of neuropeptide y
PL311736A1 (en) Derivatives of 1h-imidazoles
GB2289714B (en) Engaging structure of retainer
PL313619A1 (en) Derivatives of piperydine
PL310443A1 (en) Derivatives of pyrolo-pyridine
PL297904A1 (en) Method of obtaining bisephenol
PL306127A1 (en) Derivatives of epi-epibathydine
PL315666A1 (en) Heterocyclic compounds of therapeutic properties
PL319163A1 (en) Inhibitors of 5 alpha-reductase
ZA957113B (en) Use of N-substituted pyhenothiazines
ZA955753B (en) Heterocyclic derivatives of azolones
GB9418762D0 (en) Use of substituted cyclopentane-DI-and-triones
PL312692A1 (en) New derivatives of dialkoxy-pyridinol-benzimidazole
HU9700071D0 (en) Use of muramilpeptides
IL115614A0 (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
IL108595A0 (en) Novel derivatives of tetramethylcyclopropane
IL117813A0 (en) Use of heterocyclic compounds
PL297500A1 (en) Method of obtaining 4-phenyl-benzophenone
GB9404942D0 (en) Heterocyclic compound
GB9422764D0 (en) Use of compound
SG64924A1 (en) Inhibiting photodecompostion of 3-substituted-2- oxindoles
HRP940962B1 (en) 20-deoxo-20-amino-derivatives of 4'-demicarosyl-8a-aza-8a-homothylozine
KR0109790Y1 (en) Electronic sphygmomanometer
PL297883A1 (en) Method of obtaining substituted derivatives of phenyl quinazoline
PL55382Y1 (en) Set of symmetrisers